About: Optimizing treatment for patients with metastatic renal cell carcinoma in the central and Eastern European region

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Optimizing treatment for patients with metastatic renal cell carcinoma in the central and Eastern European region Goto Sponge Distinct Permalink

An Entity of Type : http://linked.opendata.cz/ontology/domain/vavai/Vysledek, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	skos:Concept http://linked.opendata.cz/ontology/domain/vavai/Vysledek
rdfs:seeAlso	http://dx.doi.org/10.1517/14656566.2012.647406
Description	Belarus, Bulgaria, Croatia, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Poland, Republic of Moldova, Romania, Russian Federation, Serbia, Slovakia, Slovenia and the Ukraine represent a collection of Central and Eastern European (CEE) countries in which the epidemiology and treatment of cancer varies greatly between and within countries. Current challenges include non-adherence to current treatment guidelines, restrictions in access and reimbursement for new therapies, and a lack of basic oncology programs. Metastatic renal cell carcinoma (mRCC) is a malignancy with historically poor prognosis. In CEE countries, the incidence and mortality rates of mRCC are among the highest in the world. Fortunately, mRCC represents a cancer for which a number of new targeted therapies have recently demonstrated benefit, resulting in new evidence-based treatment guidelines. Incorporating these mRCC treatment recommendations into the routine care of patients with mRCC in CEE countries would represent a major step forward for cancer care in this region. Belarus, Bulgaria, Croatia, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Poland, Republic of Moldova, Romania, Russian Federation, Serbia, Slovakia, Slovenia and the Ukraine represent a collection of Central and Eastern European (CEE) countries in which the epidemiology and treatment of cancer varies greatly between and within countries. Current challenges include non-adherence to current treatment guidelines, restrictions in access and reimbursement for new therapies, and a lack of basic oncology programs. Metastatic renal cell carcinoma (mRCC) is a malignancy with historically poor prognosis. In CEE countries, the incidence and mortality rates of mRCC are among the highest in the world. Fortunately, mRCC represents a cancer for which a number of new targeted therapies have recently demonstrated benefit, resulting in new evidence-based treatment guidelines. Incorporating these mRCC treatment recommendations into the routine care of patients with mRCC in CEE countries would represent a major step forward for cancer care in this region. (en)
Title	Optimizing treatment for patients with metastatic renal cell carcinoma in the central and Eastern European region Optimizing treatment for patients with metastatic renal cell carcinoma in the central and Eastern European region (en)
skos:prefLabel	Optimizing treatment for patients with metastatic renal cell carcinoma in the central and Eastern European region Optimizing treatment for patients with metastatic renal cell carcinoma in the central and Eastern European region (en)
skos:notation	RIV/00064165:_____/12:12916!RIV13-MZ0-00064165
http://linked.open...avai/predkladatel	Všeobecná fakultní nemocnice v Praze
http://linked.open...avai/riv/aktivita	V
http://linked.open...avai/riv/aktivity	V
http://linked.open...iv/cisloPeriodika	2
http://linked.open...vai/riv/dodaniDat	2013
http://linked.open...aciTvurceVysledku	Petruželka, Luboš
http://linked.open.../riv/druhVysledku	J - Článek v odborném periodiku
http://linked.open...iv/duvernostUdaju	S - Úplné a pravdivé údaje nepodléhající ochraně podle zvláštních právních předpisů
http://linked.open...titaPredkladatele	Všeobecná fakultní nemocnice v Praze / (nerozlišená součást)
http://linked.open...dnocenehoVysledku	157019
http://linked.open...ai/riv/idVysledku	RIV/00064165:_____/12:12916
http://linked.open...riv/jazykVysledku	eng - angličtina
http://linked.open.../riv/klicovaSlova	Bevacizumab; cytokines; everolimus; metastatic renal cell carcinoma; molecular-targeted agents; pazopanib; receptor tyrosine kinase inhibitors; sorafenib; sunitinib; temsirolimus (en)
http://linked.open.../riv/klicoveSlovo	Bevacizumab sunitinib pazopanib everolimus temsirolimus sorafenib cytokines metastatic renal cell carcinoma molecular-targeted agents receptor tyrosine kinase inhibitors
http://linked.open...odStatuVydavatele	GB - Spojené království Velké Británie a Severního Irska
http://linked.open...ontrolniKodProRIV	[63C5CD5C5F16]
http://linked.open...i/riv/nazevZdroje	Expert Opinion on Pharmacotherapy
http://linked.open...in/vavai/riv/obor	FR
http://linked.open...ichTvurcuVysledku	1 (xsd:int)
http://linked.open...cetTvurcuVysledku	12 (xsd:int)
http://linked.open...UplatneniVysledku	2012
http://linked.open...v/svazekPeriodika	13
http://linked.open...iv/tvurceVysledku	Petruželka, Luboš Mego, Michal Ciuleanu, Tudor Kharkevich, Galina Mardiak, Jozef Padrik, Peter Purkalne, Gunta Shparyk, Yaroslav Skrbinc, Breda Szczylik, Cezary Torday, Laszlo Vrdoljak, Eduard
http://linked.open...ain/vavai/riv/wos	000299091900002
issn	1465-6566
number of pages	16 (xsd:int)
is http://linked.open...avai/riv/vysledek of	Optimizing treatment for patients with metastatic renal cell carcinoma in the central and Eastern European region

Faceted Search & Find service v1.16.118 as of Jun 21 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 58 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software